Preclinical evaluation of the PI3K-mTOR dual inhibitor PF-04691502 as a novel therapeutic drug in nasopharyngeal carcinoma. (Q39105272)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23975511%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

title

Preclinical evaluation of the PI3K-mTOR dual inhibitor PF-04691502 as a novel therapeutic drug in nasopharyngeal carcinoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23975511%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23975511%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Herbert Loong

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23975511%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Brigette Ma

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23975511%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Anthony Tak-Cheung Chan

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23975511%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

author name string

Connie W C Hui

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23975511%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Cecilia P Y Lau

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23975511%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Edwin P Hui

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23975511%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

publication date

24 August 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23975511%20AND%20SRC:MED&resulttype=core&format=json

Investigational New Drugs

8 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23975511%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

volume

31

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23975511%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

page(s)

1399-1408

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23975511%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23975511%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s10637-013-0007-z

8 March 2020

exact match

0 references

cites work

Epstein-Barr virus encoded latent membrane protein 1 regulates mTOR signaling pathway genes which predict poor prognosis of nasopharyngeal carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0007-Z

Update on the management and therapeutic monitoring of advanced nasopharyngeal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0007-Z

Overproduction of cyclin D1 is dependent on activated mTORC1 signal in nasopharyngeal carcinoma: implication for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0007-Z

Differential signaling pathways are activated in the Epstein-Barr virus-associated malignancies nasopharyngeal carcinoma and Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0007-Z

The activity of mTOR inhibitor RAD001 (everolimus) in nasopharyngeal carcinoma and cisplatin-resistant cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0007-Z

PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0007-Z

In vivo activity of combined PI3K/mTOR and MEK inhibition in a Kras(G12D);Pten deletion mouse model of ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0007-Z

PI3K/mTOR inhibition can impair tumor invasion and metastasis in vivo despite a lack of antiproliferative action in vitro: implications for targeted therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0007-Z

Combination of a MEK inhibitor at sub-MTD with a PI3K/mTOR inhibitor significantly suppresses growth of lung adenocarcinoma tumors in Kras(G12D-LSL) mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0007-Z

Preclinical evaluation of the AKT inhibitor MK-2206 in nasopharyngeal carcinoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0007-Z

Preclinical activity of gefitinib in non-keratinizing nasopharyngeal carcinoma cell lines and biomarkers of response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0007-Z

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0007-Z

GDC-0941, a novel class I selective PI3K inhibitor, enhances the efficacy of docetaxel in human breast cancer models by increasing cell death in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0007-Z

Effect of PI3K/Akt pathway inhibition-mediated G1 arrest on chemosensitization in ovarian cancer cells

21 January 2018

1 reference

12 December 2020

Overexpression of phospho-Akt correlates with phosphorylation of EGF receptor, FKHR and BAD in nasopharyngeal carcinoma

1 reference

12 December 2020

PF-04691502 triggers cell cycle arrest, apoptosis and inhibits the angiogenesis in hepatocellular carcinoma cells

1 reference

12 December 2020

Preclinical evaluation of combined TKI-258 and RAD001 in hepatocellular carcinoma.

1 reference

12 December 2020

PI3K/mTOR inhibitor PF-04691502 antitumor activity is enhanced with induction of wild-type TP53 in human xenograft and murine knockout models of head and neck cancer

1 reference

12 December 2020

10.1007/S10637-013-0007-Z

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23975511%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

1 reference